-
Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page
Allergan is losing sales to generic competition
- Thread starter anonymous
- Start date
-
- Tags
- None
It ain't over til the fat lady sings.
There is appeal still pending and no generic has been approved.
There is appeal still pending and no generic has been approved.
Shire has a competing eye drop thats taking sales away.
BS is missing the simple answer!
Buy Shire! He likes buying, and here is a win/win, if another generic comes out......Buy It!
Growth Pharma is back!
Yeeeeeeeeeeha!
Buy Shire! He likes buying, and here is a win/win, if another generic comes out......Buy It!
Growth Pharma is back!
Yeeeeeeeeeeha!
Afraid it's too late. Didn't Baxalta buy Shire?
I've wondered why they did buy them when they had the chance. Allergan is definitely behind the 8 ball on a market that they were the leaders in. Time to move beyond Cyclosporine.
I've wondered why they did buy them when they had the chance. Allergan is definitely behind the 8 ball on a market that they were the leaders in. Time to move beyond Cyclosporine.
Shire bought Baxalta! Any who cares BS just needs to buy something, how about Teva? 
How about Gilead or Amgen?
Gilead just bought Kite so they bought into the viral gene therapy market.
Gilead just bought Kite so they bought into the viral gene therapy market.
Kite is actually in the CAR-T market, not gene therapy. Slightly different, but every bit as viral right now.